Last quarter (Q3 2023), Xenetic Biosciences's total revenue was $611.20K, an increase of Infinity% from the same quarter last year. In Q3, Xenetic Biosciences's net income was $-1.06M. See Xenetic Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 2.36M	$ 1.71M	$ 1.16M	$ 436.94K	$ 17.07K	$ 0.00
Cost of Revenue	-	-	-	-	-	$ 0.00
Gross Profit	$ 4.75M	$ 1.71M	$ 1.16M	-	-	$ 0.00
Operating Expense	$ 3.08M	$ 8.42M	$ 6.91M	$ 5.13M	$ 9.62M	$ 7.28M
Operating Income	$ -5.92M	$ -8.42M	$ -6.91M	$ -4.69M	$ -9.60M	$ -7.28M
Net Non Operating Interest Income Expense	$ 351.81K	$ 167.15K	$ 100.47K	$ 126.17K	$ 108.49K	$ 509.00
Other Income Expense	$ -2.38M	$ -1.71M	$ -1.16M	$ -9.24M	$ -3.28M	$ -24.64K
Pretax Income	$ -6.43M	$ -6.55M	$ -5.65M	$ -13.81M	$ -12.78M	$ -7.30M
Tax Provision	-	-	-	$ -2.92M	$ 0.00	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -4.45M	$ -6.55M	$ -5.65M	$ -10.89M	$ -18.06M	$ -7.30M
Basic EPS	$ -2.03	$ -0.46	-	$ -1.70	$ -6.33	$ -9.66
Diluted EPS	$ -2.03	$ -0.46	$ -5.50	$ -1.70	$ -6.33	$ -9.66
Basic Average Shares	$ 32.45M	$ 14.22M	$ 1.03M	$ 6.39M	$ 2.85M	$ 756.01K
Diluted Average Shares	$ 32.45M	$ 14.22M	$ 1.03M	$ 6.39M	$ 2.85M	$ 756.01K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 3.08M	$ 8.42M	$ 6.91M	$ 5.13M	$ 9.62M	$ 7.28M
Interest Expense	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	$ -4.45M	$ -6.55M	$ -5.65M	$ -10.89M	$ -12.78M	$ -7.30M
Normalized Income	$ -830.26K	-	-	$ -3.60M	$ -9.49M	$ -7.30M
Ebit	$ -6.56M	$ -6.72M	$ -5.75M	$ -4.69M	$ -9.60M	$ -7.28M
Ebitda	$ -5.51M	$ -6.69M	$ -5.71M	$ -4.67M	$ -9.58M	$ -7.26M

Currency in USD

Xenetic Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing